Triple-Drug cocktail aims to keep lung cancer at bay
NCT ID NCT03830918
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs—niraparib, temozolomide, and atezolizumab—in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the best dose and see if the combination works better than atezolizumab alone as maintenance therapy after initial chemotherapy. The trial involves 59 participants and is currently active but not recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- niraparib, temozolomide, and atezolizumab
- What this could lead to
- If successful, this combination could offer a more effective maintenance therapy for extensive-stage small cell lung cancer, potentially extending the time before the cancer progresses.
- What could go wrong
- This is an early-phase trial (phase 1b/2) with a small number of participants (59). The combination may cause significant side effects, and it is not yet known if it will improve survival compared to standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?